Wall Street analysts predict that Otonomy Inc (NASDAQ:OTIC) will post earnings per share of ($0.52) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Otonomy’s earnings, with estimates ranging from ($0.54) to ($0.50). Otonomy reported earnings of ($0.42) per share in the same quarter last year, which would suggest a negative year over year growth rate of 23.8%. The company is expected to report its next quarterly earnings report on Monday, March 2nd.
According to Zacks, analysts expect that Otonomy will report full-year earnings of ($1.54) per share for the current year, with EPS estimates ranging from ($1.64) to ($1.43). For the next fiscal year, analysts expect that the firm will post earnings of ($1.32) per share, with EPS estimates ranging from ($1.60) to ($0.85). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Otonomy.
Otonomy (NASDAQ:OTIC) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.12. The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.31 million. Otonomy had a negative return on equity of 72.06% and a negative net margin of 6,516.78%.
Several institutional investors have recently made changes to their positions in the stock. Man Group plc boosted its position in shares of Otonomy by 4.5% during the 2nd quarter. Man Group plc now owns 150,640 shares of the biopharmaceutical company’s stock valued at $414,000 after purchasing an additional 6,500 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Otonomy by 0.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,176,798 shares of the biopharmaceutical company’s stock valued at $3,236,000 after purchasing an additional 5,768 shares in the last quarter. Eversept Partners LP boosted its position in shares of Otonomy by 8.0% during the 2nd quarter. Eversept Partners LP now owns 194,429 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 14,329 shares in the last quarter. BlackRock Inc. boosted its position in shares of Otonomy by 1.0% during the 2nd quarter. BlackRock Inc. now owns 844,466 shares of the biopharmaceutical company’s stock valued at $2,322,000 after purchasing an additional 8,148 shares in the last quarter. Finally, Sofinnova Investments Inc. boosted its position in shares of Otonomy by 30.6% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,337,568 shares of the biopharmaceutical company’s stock valued at $3,679,000 after purchasing an additional 313,703 shares in the last quarter. Institutional investors own 53.28% of the company’s stock.
Shares of OTIC stock traded down $0.07 on Friday, hitting $2.43. The company had a trading volume of 31,100 shares, compared to its average volume of 74,867. The firm has a market cap of $77.49 million, a P/E ratio of -1.47 and a beta of 2.48. The stock’s 50-day moving average is $2.25 and its two-hundred day moving average is $2.44. The company has a debt-to-equity ratio of 0.60, a quick ratio of 6.66 and a current ratio of 6.66. Otonomy has a twelve month low of $1.50 and a twelve month high of $3.15.
Otonomy Company Profile
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
Featured Article: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.